Resmed Inc (RMD)
NYSE:RMD
Want to see RMD full AI Analyst Report?
RMD Stock Chart & Stats
$228.12
-$0.23(-0.10%)
At close: 4:00 PM EST
$228.12
-$0.23(-0.10%)
Day’s Range― - ―
52-Week Range$180.27 - $293.81
Previous CloseN/A
Volume178.41K
Average Volume (3M)1.61M
Market Cap
$28.57B
Enterprise Value$26.83B
Total Cash (Recent Filing)$1.66B
Total Debt (Recent Filing)$843.17M
Price to Earnings (P/E)19.0
Beta0.60
Next Earnings
Jul 30, 2026EPS Estimate
2.89Next Dividend Ex-DateN/A
Dividend Yield0.92%
Share Statistics
EPS (TTM)10.38
Shares Outstanding145,056,380
10 Day Avg. Volume1,812,554
30 Day Avg. Volume1,612,665
Financial Highlights & Ratios
PEG Ratio0.72
Price to Book (P/B)6.34
Price to Sales (P/S)7.36
P/FCF Ratio22.78
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue4.84
Enterprise Value/Gross Profit7.85
Enterprise Value/Ebitda12.76
Forecast
1Y Price Target
$270.10Price Target Upside18.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)11.11
Revenue Forecast (FY)$5.65B
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Margin ExpansionResMed's sustained ~62% gross margin and recent +290 bps improvement reflect durable product mix, manufacturing scale, and supply‑chain gains. Management's explicit multi‑year margin accretion plan to 2030 signals structural focus on margin drivers, supporting long‑term operating profit expansion and resilience to cyclical demand shifts.
Strong Cash Generation And Conservative Balance SheetConsistent operating cash flow well above net income and a net cash position provide durable financial flexibility. Low leverage (debt/equity ~0.13) plus demonstrated buybacks and dividends enable M&A, R&D funding and shareholder returns without stressing liquidity, supporting execution of the 5‑year growth strategy.
Recurring Consumables And SaaS‑backed Installed BaseA large installed device base, recurring mask/accessory demand and cloud software create high‑quality, repeatable revenue. Consumables and SaaS increase customer stickiness and margin stability, while new mask product adoption and connected care deepen clinical engagement and cross‑sell potential over multiple years.
Bears Say
RCS (residential Care Software) UnderperformanceRCS is a strategic SaaS vertical intended to boost recurring revenue and margins; its slow growth indicates execution and market adoption challenges. If RCS fails to reaccelerate, expected SaaS margin expansion and diversification will be delayed, pressuring medium‑term revenue mix improvement and investor expectations.
Rising Operating Expenses And Integration DilutionElevated SG&A and R&D to fund growth, product launches and acquisitions can compress operating leverage despite gross margin gains. Integration and acquisition dilution (Noctrix near‑term EPS drag) raise the bar for execution: sustained revenue upside is required to offset higher opex and preserve free cash flow growth.
Reimbursement & Channel Economics Risk For New MasksPremium masks face structural reimbursement variability across states and payers; constrained HME economics or payer pushback could limit adoption or force cash‑pay models. That dampens addressable market growth and could cap margin upside from higher‑priced product tiers unless ResMed secures broader reimbursement or direct‑pay pathways.
Resmed News
RMD FAQ
What was Resmed Inc’s price range in the past 12 months?
Resmed Inc lowest stock price was $180.26 and its highest was $293.81 in the past 12 months.
What is Resmed Inc’s market cap?
Resmed Inc’s market cap is $28.57B.
When is Resmed Inc’s upcoming earnings report date?
Resmed Inc’s upcoming earnings report date is Jul 30, 2026 which is in 50 days.
How were Resmed Inc’s earnings last quarter?
Resmed Inc released its earnings results on Apr 30, 2026. The company reported $2.86 earnings per share for the quarter, beating the consensus estimate of $2.795 by $0.065.
Is Resmed Inc overvalued?
According to Wall Street analysts Resmed Inc’s price is currently Undervalued.
Does Resmed Inc pay dividends?
Resmed Inc pays a Quarterly dividend of $0.6 which represents an annual dividend yield of 0.92%. See more information on Resmed Inc dividends here
What is Resmed Inc’s EPS estimate?
Resmed Inc’s EPS estimate is 2.89.
How many shares outstanding does Resmed Inc have?
Resmed Inc has 145,056,380 shares outstanding.
What happened to Resmed Inc’s price movement after its last earnings report?
Resmed Inc reported an EPS of $2.86 in its last earnings report, beating expectations of $2.795. Following the earnings report the stock price went down -4.111%.
Which hedge fund is a major shareholder of Resmed Inc?
Currently, no hedge funds are holding shares in RMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Resmed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$270.10 (18.40% Upside)
$270.10 (18.40% Upside)
Blogger Sentiment
Bullish
RMD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 6.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.76%
12-Months-Change
Fundamentals
Return on Equity
24.41%
Trailing 12-Months
Asset Growth
16.09%
Trailing 12-Months
Company Description
Resmed Inc
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
RMD Company Deck
RMD Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly positive operational and financial picture: durable revenue growth (11% headline, 8% constant), material gross margin expansion (+290 bps YoY), double‑digit EPS growth (~21%), strong free cash flow and capital returns, successful product rollouts (fabric masks, AirSense 11) and large real‑world evidence supporting a GLP‑1 demand tailwind. Management acknowledged and is actively managing a set of medium‑term headwinds — including rising SG&A and R&D investments, isolated investment write‑downs, RCS vertical challenges, component cost pressures, and near‑term acquisition dilution — but positioned these as manageable given a strong balance sheet, ongoing supply chain productivity initiatives, and targeted M&A.View all RMD earnings summariesRMD Revenue Breakdown
51.79% Devices
35.75% Masks and other
12.46% Software as a Service
RMD Stock 12 Month Forecast
Average Price Target
$270.10
▲(18.40% Upside)
Technical Analysis
Ownership Overview
0.53% Insiders
16.74% Mutual Funds
11.12% Other Institutional Investors
43.75% Public Companies and Individual Investors